{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:16:02Z","timestamp":1764587762066},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["RNCE035"],"award-info":[{"award-number":["RNCE035"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Friedrich-Alexander University, Erlangen"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.canlet.2015.07.025","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T12:50:26Z","timestamp":1438087826000},"page":"147-156","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma"],"prefix":"10.1016","volume":"367","author":[{"given":"Sara","family":"Steinmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Gali-Muhtasib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Racha","family":"Al-Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghida","family":"Abou Merhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Agaimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Schneider-Stock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.07.025_bib0010","author":"N.C. Institute site"},{"key":"10.1016\/j.canlet.2015.07.025_bib0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.07.025_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/his.12267","article-title":"The evolving classification of soft tissue tumours \u2013 an update based on the new 2013 WHO classification","volume":"64","author":"Fletcher","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2015.07.025_bib0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.sla.0000141710.74073.0d","article-title":"The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma","volume":"240","author":"Eilber","year":"2004","journal-title":"Ann. Surg"},{"key":"10.1016\/j.canlet.2015.07.025_bib0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.sla.0000086542.11899.38","article-title":"Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma","volume":"238","author":"Singer","year":"2003","journal-title":"Ann. Surg"},{"key":"10.1016\/j.canlet.2015.07.025_bib0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/08998280.2008.11928435","article-title":"Current treatment of soft tissue sarcoma","volume":"21","author":"Steen","year":"2008","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"10.1016\/j.canlet.2015.07.025_bib0040","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","article-title":"Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor","volume":"66","author":"Bauer","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.025_bib0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CCO.0b013e3283477ac2","article-title":"Treatment of gastrointestinal stromal tumor after imatinib and sunitinib","volume":"23","author":"Montemurro","year":"2011","journal-title":"Curr. Opin. Oncol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0050","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-07-5256","article-title":"AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis","volume":"68","author":"Eccles","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.025_bib0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-5521(01)00015-1","article-title":"A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells","volume":"8","author":"Chiosis","year":"2001","journal-title":"Chem. Biol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1476-4598-9-257","article-title":"Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option","volume":"9","author":"Willems","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2015.07.025_bib0065","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc"},{"key":"10.1016\/j.canlet.2015.07.025_bib0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ijc.20611","article-title":"Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin","volume":"113","author":"Bagatell","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2015.07.025_bib0080","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdu202","article-title":"Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor\/well-differentiated LPS (ALT\/WD-LPS): a French Sarcoma Group (GSF-GETO) study","volume":"25","author":"Cassier","year":"2014","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0085","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.18632\/oncotarget.2023","article-title":"Identification of a gene expression driven progression pathway in myxoid liposarcoma","volume":"5","author":"De Cecco","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2015.07.025_bib0090","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2217\/fon.14.90","article-title":"Liposarcoma miRNA signatures identified from genome-wide miRNA expression profiling","volume":"10","author":"Zhou","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0095","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.025_bib0100","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1038\/cddis.2013.101","article-title":"Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor","volume":"4","author":"Fu","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.canlet.2015.07.025_bib0105","doi-asserted-by":"crossref","first-page":"e1003048","DOI":"10.1371\/journal.ppat.1003048","article-title":"Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins","volume":"8","author":"Chen","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.canlet.2015.07.025_bib0110","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3892\/ijo.2013.2130","article-title":"Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells","volume":"43","author":"Zitzmann","year":"2013","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0115","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1158\/1535-7163.MCT-13-0284","article-title":"Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax","volume":"12","author":"He","year":"2013","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.canlet.2015.07.025_bib0120","doi-asserted-by":"crossref","first-page":"e35436","DOI":"10.1371\/journal.pone.0035436","article-title":"The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage","volume":"7","author":"Zaidi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.07.025_bib0125","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/0008-5472.CAN-08-0884","article-title":"Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells","volume":"68","author":"Gali-Muhtasib","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.07.025_bib0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.108.050807","article-title":"90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2\/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1","volume":"75","author":"Tse","year":"2009","journal-title":"Mol. Pharmacol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0135","doi-asserted-by":"crossref","first-page":"e113110","DOI":"10.1371\/journal.pone.0113110","article-title":"Normal and functional TP53 in genetically stable myxoid\/round cell liposarcoma","volume":"9","author":"Stahlberg","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.07.025_bib0140","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.biocel.2007.03.001","article-title":"Histone deacetylase inhibitors: signalling towards p21cip1\/waf1","volume":"39","author":"Ocker","year":"2007","journal-title":"Int. J. Biochem. Cell Biol"},{"key":"10.1016\/j.canlet.2015.07.025_bib0145","doi-asserted-by":"crossref","first-page":"483154","DOI":"10.1155\/2011\/483154","article-title":"Liposarcoma: molecular genetics and therapeutics","volume":"2011","author":"Conyers","year":"2011","journal-title":"Sarcoma"},{"key":"10.1016\/j.canlet.2015.07.025_bib0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat. Rev"},{"key":"10.1016\/j.canlet.2015.07.025_bib0155","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2015.07.025_bib0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","article-title":"Targeting PI3 kinase in cancer","volume":"146C","author":"Bauer","year":"2015","journal-title":"Pharmacol. Ther"},{"key":"10.1016\/j.canlet.2015.07.025_bib0165","doi-asserted-by":"crossref","first-page":"e93996","DOI":"10.1371\/journal.pone.0093996","article-title":"Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS ONE"},{"issue":"Suppl. 2","key":"10.1016\/j.canlet.2015.07.025_bib0170","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"De Luca","year":"2012","journal-title":"Expert Opin. Ther. Targets"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515004802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515004802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T08:38:49Z","timestamp":1652949529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515004802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0304383515004802"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.07.025","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}